If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Previous Alendronate Users May Benefit From Cyclic Administration of Teriparatide: Presented at ASBMR By John Otrompke DENVER -- September 15, 2009 -- Teriparatide increases bone mineral density (BMD) at the hip equally in women, whether or not they had previously been treated with alendronate, and regardless of whether the teriparatide was administered daily or by a cyclic method. When measured at the spine, however, women who had previously been given alendronate improved more when the teriparatide was administered in a cyclic dose, according a study presented here at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR). “Women who have previously been treated with alendronate respond very well to teriparatide,” said Felicia Cosman, MD, Columbia University, New York, New York, on September 13. “If they respond well, and meet the criteria for using the drug, teriparatide is a very good way to treat these women.” For the study, researchers randomised 139 postmenopausal women with osteoporosis, (mean age, 65 years), to receive either daily treatment with teriparatide or to receive the drug in a cyclic dose (3 months on, 3 months off). Seventy-two of the women had previously been treated with alendronate, whereas 67 women were treatment-naïve. At the meeting, Dr. Cosman presented data from the first 69 women who had completed 15 months of the trial. The preliminary results were found in 20 treatment-naïve women on cyclic therapy and 13 on daily therapy, and in those who had taken alendronate -- 15 on cyclic and 21 on daily therapy. The alendronate-exposed group had been on alendronate for 5.5 years on average and some continued to take the drug. In the daily group, spine BMD increased 4.6% in the alendronate-treated women compared with 6.8% in treatment-naïve women. In the cyclic group, spine BMD increased 6.5% in alendronate-treated women, compared with 6.7% in treatment-naïve women. In the hip, on the other hand, the daily group experienced an increase of 1.8% in alendronate-treated women, compared with 2.9% in treatment-naïve women. For the cyclic group, alendronate women increased hip BMD by 2.5% compared with 1.8% in the treatment-naïve group. “The study in ongoing,” said Dr. Cosman. “I presented 15 months of data, and I probably will present the 2-year data next year. We’re hoping to extend the study for 4 years. We think over 4 years the cyclic group will do better than the daily group did over 2 years.” The impact of teriparatide on the daily group peaked at 9 to 12 months, she added. While there are some counter-indications to teriparatide use, including radiation exposure, Paget’s disease, cancer, and hyperthyroidism, they are not specific to prior alendronate exposure, according to Dr. Cosman. [Presentation title: Cyclic vs Daily Teriparatide Therapy in Previously Untreated Postmenopausal Women and in Those on Prior Alendronate. Abstract SA1100]
|
